Monday, March 29, 2021 3:14:53 PM
New York Yankees and Duke Basketball
Recent EWTX News
- Edgewise Therapeutics Doses First Patient in Phase 2 CIRRUS-HCM Trial of EDG-7500 in Obstructive Hypertrophic Cardiomyopathy (HCM) • Business Wire • 05/06/2024 12:00:00 PM
- Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies • Business Wire • 04/23/2024 12:00:00 PM
- Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker) • Business Wire • 04/15/2024 08:05:00 PM
- Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session • Business Wire • 03/28/2024 12:00:00 PM
- Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024 • Business Wire • 03/27/2024 12:00:00 PM
- Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024 • Business Wire • 03/05/2024 01:00:00 PM
- Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference • Business Wire • 02/28/2024 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 01:07:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/22/2024 01:00:13 PM
- Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights • Business Wire • 02/22/2024 01:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:43:00 PM
- Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) • Business Wire • 02/13/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 10:42:31 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/07/2024 09:15:46 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/19/2024 09:54:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 01:44:25 PM
- Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock • Business Wire • 01/19/2024 01:37:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 11:05:44 AM
- Form S-3MEF - Registration adding securities to prior Form S-3 registration [Rule 462(b)] • Edgar (US Regulatory) • 01/19/2024 11:04:18 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/19/2024 11:02:09 AM
- Edgewise Therapeutics Highlights 2023 Accomplishments and Anticipated Milestones for 2024 at the 42nd Annual J.P. Morgan Healthcare Conference • Business Wire • 01/09/2024 01:39:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 09:38:37 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 12/26/2023 09:32:26 PM
- Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024 • Business Wire • 12/19/2023 01:00:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM